{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:47:03Z","timestamp":1793818023545,"version":"4.6.1"},"reference-count":39,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Clinical laboratories play a vital role in the healthcare system. Objective medical data provided by clinical laboratories supports approximately 60\u201370% of clinical decisions, however, evidence supporting this claim is poorly documented and laboratories still lack visibility, despite their indisputable impact on patient care and public health. The International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on Outcome Studies in Laboratory Medicine (TF-OSLM) was recently developed to support directed research evaluating the role of laboratory medicine on clinical outcomes. Establishing and documenting this evidence is key to enhance visibility of the field in the eye of the public and other healthcare professionals together with optimizing patient outcomes and health care system operations. In this review, we discuss four areas that exemplify the contribution of laboratory medicine directly to patient care. This includes high-sensitivity cardiac troponin (hs-cTn) and N-terminal pro-B-type natriuretic peptide\/B-type natriuretic peptides (NT-proBNP\/BNP) for the diagnosis and prognosis of myocardial infarction and heart failure, respectively, and procalcitonin for the management of sepsis and antibiotic stewardship. Emerging markers of traumatic brain injury and the role of laboratory medicine in the fight against the COVID-19 pandemic are discussed along with an introduction to plans of IFCC TF-OSLM.<\/jats:p>","DOI":"10.1515\/cclm-2022-1075","type":"journal-article","created":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T12:20:36Z","timestamp":1669551636000},"page":"666-673","source":"Crossref","is-referenced-by-count":45,"title":["Central role of laboratory medicine in public health and patient care"],"prefix":"10.1515","volume":"61","author":[{"given":"Pyper","family":"Olver","sequence":"first","affiliation":[{"name":"CALIPER Program, Department of Paediatric Laboratory Medicine , The Hospital for Sick Children , Toronto , ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Kathryn","family":"Bohn","sequence":"additional","affiliation":[{"name":"CALIPER Program, Department of Paediatric Laboratory Medicine , The Hospital for Sick Children , Toronto , ON , Canada"},{"name":"Department of Laboratory Medicine and Pathobiology , University of Toronto , Toronto , ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khosrow","family":"Adeli","sequence":"additional","affiliation":[{"name":"CALIPER Program, Department of Paediatric Laboratory Medicine , The Hospital for Sick Children , Toronto , ON , Canada"},{"name":"Department of Laboratory Medicine and Pathobiology , University of Toronto , Toronto , ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"key":"2024081409131501495_j_cclm-2022-1075_ref_001","unstructured":"Freedman, DB. Towards better test utilization\u00a0\u2013 strategies to improve physician ordering and their impact on patient outcomes. eJIFCC 2015;26:15\u201330."},{"key":"2024081409131501495_j_cclm-2022-1075_ref_002","doi-asserted-by":"crossref","unstructured":"Hallworth, MJ, Epner, PL, Ebert, C, Fantz, CR, Faye, SA, Higgins, TN, et al.. Current evidence and future perspectives on the effective practice of patient-centered laboratory medicine. Clin Chem 2015;61:589\u201399. https:\/\/doi.org\/10.1373\/clinchem.2014.232629.","DOI":"10.1373\/clinchem.2014.232629"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_003","unstructured":"Kenneth Research. Global in-vitro diagnostics (IVD) market to garner a revenue of USD 135167.7 million by 2031 and touch a CAGR of 4.6% during 2022\u20132031; market to grow on account of growing prevalence of chronic and infectious diseases [Internet] GlobeNewswire by Notified; 2022. Available from: https:\/\/www.globenewswire.com\/en\/news-release\/2022\/05\/16\/2443598\/0\/en\/Global-In-Vitro-Diagnostics-IVD-Market-to-Garner-a-Revenue-of-USD-135167-7-Million-by-2031-and-Touch-a-CAGR-of-4-6-During-2022-2031-Market-to-Grow-on-Account-of-Growing-Prevalence-.html [Accessed 26 Sep 2022]."},{"key":"2024081409131501495_j_cclm-2022-1075_ref_004","doi-asserted-by":"crossref","unstructured":"Hallworth, MJ. The \u201870% claim:\u2019 what is the evidence base? Ann Clin Biochem 2011;48:487\u20138. https:\/\/doi.org\/10.1258\/acb.2011.011177.","DOI":"10.1258\/acb.2011.011177"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_005","doi-asserted-by":"crossref","unstructured":"Rohr, UP, Binder, C, Dieterle, T, Giusti, F, Messina, CGM, Toerien, E, et al.. The value of in\u00a0vitro diagnostic testing in medical practice: a status report. PLoS One 2016;11:e0149856. https:\/\/doi.org\/10.1371\/journal.pone.0149856.","DOI":"10.1371\/journal.pone.0149856"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_006","unstructured":"World Health Organization. Cardiovascular diseases [Internet]. World Health Organization; 2022. Available from: https:\/\/www.who.int\/health-topics\/cardiovascular-diseases [Accessed 29 Sep 2022]."},{"key":"2024081409131501495_j_cclm-2022-1075_ref_007","doi-asserted-by":"crossref","unstructured":"Danese, E, Montagnana, M. An historical approach to the diagnostic biomarkers of acute coronary syndrome. Ann Transl Med 2016;4:194. https:\/\/doi.org\/10.21037\/atm.2016.05.19.","DOI":"10.21037\/atm.2016.05.19"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_008","doi-asserted-by":"crossref","unstructured":"Thygesen, K, Alpert, JS, Jaffe, AS, Chaitman, BR, Bax, JJ, Morrow, DA, et al.. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol 2018;72:2231\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.08.1038.","DOI":"10.1016\/j.jacc.2018.08.1038"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_009","doi-asserted-by":"crossref","unstructured":"Anand, A, Lee, KK, Chapman, AR, Ferry, AV, Adamson, PD, Strachan, FE, et al.. High-sensitivity cardiac troponin on presentation to rule out myocardial infarction: a stepped-wedge cluster randomized controlled trial. Circulation 2021;143:2214\u201324. https:\/\/doi.org\/10.1161\/circulationaha.120.052380.","DOI":"10.1161\/CIRCULATIONAHA.120.052380"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_010","doi-asserted-by":"crossref","unstructured":"Ljung, L, Lindahl, B, Eggers, KM, Frick, M, Linder, R, L\u00f6fmark, HB, et al.. A rule-out strategy based on high-sensitivity troponin and HEART score reduces hospital admissions. Ann Emerg Med 2019;73:491\u20139. https:\/\/doi.org\/10.1016\/j.annemergmed.2018.11.039.","DOI":"10.1016\/j.annemergmed.2018.11.039"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_011","doi-asserted-by":"crossref","unstructured":"Collet, JP, Thiele, H, Barbato, E, Barth\u00e9l\u00e9my, O, Bauersachs, J, Bhatt, DL, et al.. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289\u2013367.","DOI":"10.1093\/eurheartj\/ehaa909"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_012","doi-asserted-by":"crossref","unstructured":"Gulati, M, Levy, PD, Mukherjee, D, Amsterdam, E, Bhatt, DL, Birtcher, KK, et al.. 2021 AHA\/ACC\/ASE\/CHEST\/SAEM\/SCCT\/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines. Circulation 2021;144:e368\u2013454.","DOI":"10.1161\/CIR.0000000000001029"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_013","doi-asserted-by":"crossref","unstructured":"Savarese, G, Lund, LH. Global public health burden of heart failure. Card Fail Rev 2017;3:7\u201311. https:\/\/doi.org\/10.15420\/cfr.2016:25:2.","DOI":"10.15420\/cfr.2016:25:2"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_014","doi-asserted-by":"crossref","unstructured":"Kuwahara, K. The natriuretic peptide system in heart failure: diagnostic and therapeutic implications. Pharmacol Ther 2021;227:107863. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107863.","DOI":"10.1016\/j.pharmthera.2021.107863"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_015","doi-asserted-by":"crossref","unstructured":"Moe, GW, Howlett, J, Januzzi, JL, Zowall, H. N-terminal pro\u2013B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure. Circulation 2007;115:3103\u201310. https:\/\/doi.org\/10.1161\/circulationaha.106.666255.","DOI":"10.1161\/CIRCULATIONAHA.106.666255"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_016","doi-asserted-by":"crossref","unstructured":"Siebert, U, Januzzi, JL, Beinfeld, MT, Cameron, R, Gazelle, GS. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol 2006;98:800\u20135. https:\/\/doi.org\/10.1016\/j.amjcard.2006.06.005.","DOI":"10.1016\/j.amjcard.2006.06.005"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_017","doi-asserted-by":"crossref","unstructured":"Ledwidge, M, Gallagher, J, Conlon, C, Tallon, E, O\u2019Connell, E, Dawkins, I, et al.. Natriuretic peptide\u2013based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013;310:66\u201374. https:\/\/doi.org\/10.1001\/jama.2013.7588.","DOI":"10.1001\/jama.2013.7588"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_018","doi-asserted-by":"crossref","unstructured":"Ponikowski, P, Voors, AA, Anker, SD, Bueno, H, Cleland, JGF, Coats, AJS, et al.. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail 2016;18:891\u2013975. https:\/\/doi.org\/10.1002\/ejhf.592.","DOI":"10.1002\/ejhf.592"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_019","doi-asserted-by":"crossref","unstructured":"Vijayan, AL, Vanimaya, Ravindran, S, Saikant, R, Lakshmi, S, Kartik, R, et al.. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. J Intensive Care 2017;5:51. https:\/\/doi.org\/10.1186\/s40560-017-0246-8.","DOI":"10.1186\/s40560-017-0246-8"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_020","doi-asserted-by":"crossref","unstructured":"Kyriazopoulou, E, Liaskou-Antoniou, L, Adamis, G, Panagaki, A, Melachroinopoulos, N, Drakou, E, et al.. Procalcitonin to reduce long-term infection-associated adverse events in sepsis. A randomized trial. Am J Respir Crit Care Med 2021;203:202\u201310. https:\/\/doi.org\/10.1164\/rccm.202004-1201oc.","DOI":"10.1164\/rccm.202004-1201OC"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_021","doi-asserted-by":"crossref","unstructured":"Hohn, A, Schroeder, S, Gehrt, A, Bernhardt, K, Bein, B, Wegscheider, K, et al.. Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock. BMC Infect Dis 2013;13:158. https:\/\/doi.org\/10.1186\/1471-2334-13-158.","DOI":"10.1186\/1471-2334-13-158"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_022","doi-asserted-by":"crossref","unstructured":"Schuetz, P, Wirz, Y, Sager, R, Christ-Crain, M, Stolz, D, Tamm, M, et al.. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis 2018;18:95\u2013107. https:\/\/doi.org\/10.1016\/s1473-3099(17)30592-3.","DOI":"10.1016\/S1473-3099(18)30016-1"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_023","doi-asserted-by":"crossref","unstructured":"Milcent, K, Faesch, S, Gras-Le Guen, C, Dubos, F, Poulalhon, C, Badier, I, et al.. Use of procalcitonin assays to predict serious bacterial infection in young febrile infants. JAMA Pediatr 2016;170:62\u20139. https:\/\/doi.org\/10.1001\/jamapediatrics.2016.0379.","DOI":"10.1001\/jamapediatrics.2015.3210"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_024","doi-asserted-by":"crossref","unstructured":"Schuetz, P, Beishuizen, A, Broyles, M, Ferrer, R, Gavazzi, G, Gluck, EH, et al.. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clin Chem Lab Med 2019;57:1308\u201318. https:\/\/doi.org\/10.1515\/cclm-2018-1181.","DOI":"10.1515\/cclm-2018-1181"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_025","doi-asserted-by":"crossref","unstructured":"Tujula, B, H\u00e4m\u00e4l\u00e4inen, S, Kokki, H, Pulkki, K, Kokki, M. Review of clinical practice guidelines on the use of procalcitonin in infections. J Infect Dis 2020;52:227\u201334. https:\/\/doi.org\/10.1080\/23744235.2019.1704860.","DOI":"10.1080\/23744235.2019.1704860"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_026","doi-asserted-by":"crossref","unstructured":"GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 2019;18:56\u201387.","DOI":"10.1016\/S1474-4422(18)30415-0"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_027","doi-asserted-by":"crossref","unstructured":"Walker, K, Tesco, G. Molecular mechanisms of cognitive dysfunction following traumatic brain injury. Front Aging Neurosci 2013;5:1\u201325. https:\/\/doi.org\/10.3389\/fnagi.2013.00029.","DOI":"10.3389\/fnagi.2013.00029"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_028","doi-asserted-by":"crossref","unstructured":"Korley, FK, Jain, S, Sun, X, Puccio, AM, Yue, JK, Gardner, RC, et al.. Prognostic value of day-of-injury plasma GFAP and UCH-L1 concentrations for predicting functional recovery after traumatic brain injury in patients from the US TRACK-TBI cohort: an observational cohort study. Lancet Neurol 2022;21:803\u201313. https:\/\/doi.org\/10.1016\/s1474-4422(22)00256-3.","DOI":"10.1016\/S1474-4422(22)00256-3"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_029","doi-asserted-by":"crossref","unstructured":"Gill, J, Merchant-Borna, K, Jeromin, A, Livingston, W, Bazarian, J. Acute plasma tau relates to prolonged return to play after concussion. Neurol 2017;88:595\u2013602. https:\/\/doi.org\/10.1212\/wnl.0000000000003587.","DOI":"10.1212\/WNL.0000000000003587"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_030","doi-asserted-by":"crossref","unstructured":"Shahim, P, Tegner, Y, Wilson, DH, Randall, J, Skillb\u00e4ck, T, Pazooki, D, et al.. Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol 2014;71:684\u201392. https:\/\/doi.org\/10.1001\/jamaneurol.2014.367.","DOI":"10.1001\/jamaneurol.2014.367"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_031","doi-asserted-by":"crossref","unstructured":"Olivera, A, Lejbman, N, Jeromin, A, French, LM, Kim, HS, Cashion, A, et al.. Peripheral total tau in military personnel who sustain traumatic brain injuries during deployment. JAMA Neurol 2015;72:1109\u201316. https:\/\/doi.org\/10.1001\/jamaneurol.2015.1383.","DOI":"10.1001\/jamaneurol.2015.1383"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_032","doi-asserted-by":"crossref","unstructured":"Stukas, S, Higgins, V, Frndova, H, Gill, J, Hubara, E, Guerguerian, AM, et al.. Characterisation of serum total tau following paediatric traumatic brain injury: a case-control study. Lancet Child Adolesc Health 2019;3:558\u201367. https:\/\/doi.org\/10.1016\/s2352-4642(19)30194-4.","DOI":"10.1016\/S2352-4642(19)30194-4"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_033","unstructured":"Office of the Commissioner of the FDA. FDA authorizes marketing of first blood test to aid in the evaluation of concussion in adults [Internet]. FDA; 2020. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-authorizes-marketing-first-blood-test-aid-evaluation-concussion-adults [Accessed 25 Sep 2022]."},{"key":"2024081409131501495_j_cclm-2022-1075_ref_034","doi-asserted-by":"crossref","unstructured":"The Scandinavian Neurotrauma Committee (SNC), Und\u00e9n, J, Ingebrigtsen, T, Romner, B. Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults: an evidence and consensus-based update. BMC Med 2013;11:50. https:\/\/doi.org\/10.1186\/1741-7015-11-50.","DOI":"10.1186\/1741-7015-11-50"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_035","unstructured":"COVID-19 test directory [Internet]. FIND Diagnosis for all; 2022. Available from: https:\/\/www.finddx.org\/covid-19\/test-directory\/ [Accessed 23 Oct 2022]."},{"key":"2024081409131501495_j_cclm-2022-1075_ref_036","doi-asserted-by":"crossref","unstructured":"Bohn, MK, Lippi, G, Horvath, AR, Erasmus, R, Grimmler, M, Gramegna, M, et al.. IFCC interim guidelines on rapid point-of-care antigen testing for SARS-CoV-2 detection in asymptomatic and symptomatic individuals. Clin Chem Lab Med 2021;59:1507\u201315. https:\/\/doi.org\/10.1515\/cclm-2021-0455.","DOI":"10.1515\/cclm-2021-0455"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_037","doi-asserted-by":"crossref","unstructured":"Bohn, MK, Mancini, N, Loh, TP, Wang, CB, Grimmler, M, Gramegna, M, et al.. IFCC interim guidelines on molecular testing of SARS-CoV-2 infection. Clin Chem Lab Med 2020;58:1993\u20132000. https:\/\/doi.org\/10.1515\/cclm-2020-1412.","DOI":"10.1515\/cclm-2020-1412"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_038","doi-asserted-by":"crossref","unstructured":"Bohn, MK, Lippi, G, Horvath, A, Sethi, S, Koch, D, Ferrari, M, et al.. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence. Clin Chem Lab Med 2020;58:1037\u201352. https:\/\/doi.org\/10.1515\/cclm-2020-0722.","DOI":"10.1515\/cclm-2020-0722"},{"key":"2024081409131501495_j_cclm-2022-1075_ref_039","doi-asserted-by":"crossref","unstructured":"Bohn, MK, Loh, TP, Wang, CB, Mueller, R, Koch, D, Sethi, S, et al.. IFCC interim guidelines on serological testing of antibodies\u00a0against SARS-CoV-2. Clin Chem Lab Med 2020;58:2001\u20138. https:\/\/doi.org\/10.1515\/cclm-2020-1413.","DOI":"10.1515\/cclm-2020-1413"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-1075\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-1075\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T05:18:34Z","timestamp":1723612714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-1075\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,8,29]]},"published-print":{"date-parts":[[2023,3,28]]}},"alternative-id":["10.1515\/cclm-2022-1075"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2022-1075","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]}}}